Non-analgesic effects of opioids: Peripheral opioid receptors as promising targets for future anti-pruritic therapies

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6021-6024

  Reich, Adam ^a   Szepietowski, Jacek C ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anti pruritic agents; Itch; Opioids; Peripheral opioid system; Skin

Indexed keywords

ANTIPRURITIC AGENT; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; DYNORPHIN; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; KAPPA OPIATE RECEPTOR; LOPERAMIDE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; OPIATE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ANTINOCICEPTION; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DOSE RESPONSE; FIBROBLAST; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; KERATINOCYTE; MACROPHAGE; MAST CELL; MELANOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANALGESICS, OPIOID; ANIMALS; ANTIPRURITICS; DRUG DESIGN; HUMANS; PAIN; PRURITUS; RECEPTORS, OPIOID; SKIN;

EID: 84873963527     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582405     Document Type: Article

References (41)

1. Reich A, Ständer S, Szepietowski JC. Drug-induced pruritus: A review. Acta Derm Venereol 2009; 89: 236-44
2. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol 2010; 35: 2-6
3. Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998; 111: 297-301
4. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228-35.
5. Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K, et al. Deletion of muand kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol 2007; 127: 1479-88
6. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ. Regulation of human epidermal melanocyte biology by betaendorphin. J Invest Dermatol 2003; 120: 1073-80
7. Kauser S, Thody AJ, Schallreuter KU, Gummer CL, Tobin DJ. Beta-Endorphin as a regulator of human hair follicle melanocyte biology. J Invest Dermatol 2004; 123: 184-95
8. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin-where do we stand? Exp Dermatol 2009; 18: 424-30
9. Cheng B, Liu HW, Fu XB, Sheng ZY, Li JF. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol 2008; 158: 713-20
10. Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002; 110: 75-83
11. Bigliardi-Qi M, Lipp B, Sumanovski LT, Buechner SA, Bigliardi PL. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005; 210: 91-9
12. Bigliardi-Qi M, Bigliardi PL, Eberle AN, Büchner S, Rufli T. Betaendorphin stimulates cytokeratin 16 expression and downregulates mu-opiate receptor expression in human epidermis. J Invest Dermatol 2000; 114: 527-32
13. Bigliardi-Qi M, Bigliardi PL, Büchner S, Rufli T. Characterization of mu-opiate receptor in human epidermis and keratinocytes. Ann N Y Acad Sci 1999; 885: 368-71
14. Bigliardi PL, Sumanovski LT, Büchner S, Rufli T, Bigliardi-Qi M. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J Invest Dermatol 2003; 120: 145-52
15. Salemi S, Aeschlimann A, Reisch N, et al. Detection of kappa and delta opioid receptors in skin-outside the nervous system. Biochem Biophys Res Commun 2005; 338: 1012-7
16. Bigliardi-Qi M, Gaveriaux-Ruff C, Zhou H, et al. Deletion of deltaopioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 2006; 74: 174-85
17. Wintzen M, de Winter S, Out-Luiting JJ, van Duinen SG, Vermeer BJ. Presence of immunoreactive beta-endorphin in human skin. Exp Dermatol 2001; 10: 305-11
18. Nissen JB, Lund M, Stengaard-Pedersen K, Kragballe K. Enkephalin-like immunoreactivity in human skin is found selectively in a fraction of CD68-positive dermal cells: increase in enkephalin-positive cells in lesional psoriasis. Arch Dermatol Res 1997; 289: 265-71
19. Nissen JB, Kragballe K. Enkephalins modulate differentiation of normal human keratinocytes in vitro. Exp Dermatol 1997; 6: 222-9
20. Tachibana T, Nawa T. Immunohistochemical reactions of receptors to met-enkephalin, VIP, substance P, and CGRP located on Merkel cells in the rat sinus hair follicle. Arch Histol Cytol 2005; 68: 383-91
21. Zagon IS, Wu Y, McLaughlin PJ. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol 1996; 106: 490-7
22. Bigliardi PL, Büchner S, Rufli T, Bigliardi-Qi. Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. J Recept Signal Transduct Res 2002; 22: 191-9
23. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen 2005; 13: 165-74
24. Rook JM, Hasan W, McCarson KE. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology 2008; 109: 130-6
25. Rook JM, McCarson KE. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochem Pharmacol 2007; 74: 752-7
26. Nezami BG, Talab SS, Emami H, et al. Chronic upregulation of the endogenous opioid system impairs the skin flap survival in rats. Ann Plast Surg 2009; 63: 558-63.
27. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004; 84: 1155-228
28. Zouboulis CC, Baron JM, Böhm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol 2008; 17: 542-51
29. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527-31
30. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41: 533-9
31. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 1251-7
32. Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001; 418: 141-5
33. Wikström B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebocontrolled clinical studies. J Am Soc Nephrol 2005; 16: 3742-7
34. Yamamoto A, Sugimoto Y. Involvement of peripheral mu opioid receptors in scratching behavior in mice. Eur J Pharmacol 2010; 649: 336-41
35. Miyamoto T, Nojima H, Shinkado T, Nakahashi T, Kuraishi Y. Itch-associated response induced by experimental dry skin in mice. Jpn J Pharmacol 2002; 88: 285-92
36. Akiyama T, Carstens MI, Carstens E. Spontaneous itch in the absence of hyperalgesia in a mouse hindpaw dry skin model. Neurosci Lett 2010; 484: 62-5
37. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 149: 718-30
38. Mousa SA, Cheppudira BP, Shaqura M, Fischer O, Hofmann J, Hellweg R, Schäfer M. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain 2007; 130: 502-13
39. Lee CH, Chuang HY, Shih CC, Jong SB, Chang CH, Yu HS. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006; 154: 1100-7
40. Glinski W, Brodecka H, Glinska-Ferenz M, Kowalski D. Increased concentration of beta-endorphin in the sera of patients with severe atopic dermatitis. Acta Derm Venereol 1995; 75: 9-11
41. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol 2011; 165: 277-84